Researchers at UCSF have developed a robotic platform, ResMap, capable of systematically mapping therapy-resistant residual cancer cell dependencies. This system allows for the identification and treatment of rare 'persister' cells that often lead to tumor relapse. The platform has identified nine drug candidates that consistently weaken these cells, suggesting common vulnerabilities that could be exploited for future combination therapies against persistent cancer.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
21
Ali NematiWritten by Ali
